GU Cancers 2024 | 131I-MIP-1095, a novel therapeutic radiopharmaceutical, in mCRPC

Andrew Laccetti, MD, MS, Memorial Sloan Kettering Cancer Center, New York, NY, provides an overview of a dose-escalation, Phase I trial (NCT03030885) of 131I-MIP-1095, a novel therapeutic radiopharmaceutical consisting of the β-particle emitter 131I, in patients with metastatic castration-resistant prostate cancer (mCRPC). The investigational therapy is similar to 177Lu vipivotide tetraxetan (177Lu-PSMA-617), albeit with a different targeting agent. 131I-MIP-1095 was found to have promising dosimetry and safety. However, limited PSA responses were observed due to supply chain issues. This interview took place at the ASCO GU Cancers Symposium 2024 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.